INTRODUCTION
• The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor
cells and activates T cells by co-opting the endogenous T cell receptor complex, with the goal of eliciting a safe and durable
anti-tumor response. In preclinical models, TAC-engineered T cells effectively eradicate tumor cells in vitro and in vivo
without toxicities typically associated with engineered T cell products. TAC01-HER2 is an autologous T-cell product
comprising T cells expressing the HER2 TAC, which specifically recognizes HER2+ cells.
• TACTIC-2 (NCT04727151) is an open-label, multicenter phase I/II study that aims to establish safety, maximum tolerated
dose (MTD), recommended phase 2 dose (RP2D), pharmacokinetic profile, and efficacy of TAC01-HER2 in patients with HER2-
positive solid tumors by immunohistochemistry that are 1+, 2+, or 3+ (i.e. breast, lung, pancreatic, colorectal, gastric,
endometrial, ovarian, and others) who have progressed on prior anti-cancer therapies.
• We present updated preliminary data from Cohorts 1-4 (20 participants) that highlights safety and efficacy data; the study
further elucidates potential therapeutic impact on patients with HER2 overexpressed solid tumors.
